nodes	percent_of_prediction	percent_of_DWPC	metapath
Clomipramine—ALB—atherosclerosis	0.195	1	CbGaD
Clomipramine—ALB—Rosuvastatin—atherosclerosis	0.0562	0.122	CbGbCtD
Clomipramine—CYP2C19—Rosuvastatin—atherosclerosis	0.0364	0.0788	CbGbCtD
Clomipramine—CYP2C19—Simvastatin—atherosclerosis	0.0339	0.0733	CbGbCtD
Clomipramine—CYP2C19—Lovastatin—atherosclerosis	0.0332	0.0717	CbGbCtD
Clomipramine—CYP2D6—Niacin—atherosclerosis	0.0326	0.0705	CbGbCtD
Clomipramine—ABCB1—Ezetimibe—atherosclerosis	0.0294	0.0636	CbGbCtD
Clomipramine—ABCB1—Simvastatin—atherosclerosis	0.0273	0.0591	CbGbCtD
Clomipramine—ABCB1—Lovastatin—atherosclerosis	0.0268	0.0579	CbGbCtD
Clomipramine—ABCB1—Pravastatin—atherosclerosis	0.0268	0.0579	CbGbCtD
Clomipramine—CYP2D6—Simvastatin—atherosclerosis	0.0258	0.0557	CbGbCtD
Clomipramine—CYP2D6—Lovastatin—atherosclerosis	0.0252	0.0545	CbGbCtD
Clomipramine—CYP2D6—Pravastatin—atherosclerosis	0.0252	0.0545	CbGbCtD
Clomipramine—CYP3A4—Rosuvastatin—atherosclerosis	0.0176	0.0381	CbGbCtD
Clomipramine—CYP3A4—Ezetimibe—atherosclerosis	0.0176	0.0381	CbGbCtD
Clomipramine—CYP3A4—Simvastatin—atherosclerosis	0.0164	0.0354	CbGbCtD
Clomipramine—CYP3A4—Lovastatin—atherosclerosis	0.016	0.0347	CbGbCtD
Clomipramine—CYP3A4—Pravastatin—atherosclerosis	0.016	0.0347	CbGbCtD
Clomipramine—HTR2A—arteriole—atherosclerosis	0.00225	0.184	CbGeAlD
Clomipramine—HTR2A—vein—atherosclerosis	0.00134	0.11	CbGeAlD
Clomipramine—HTR2A—hindlimb—atherosclerosis	0.000893	0.0728	CbGeAlD
Clomipramine—HTR2A—appendage—atherosclerosis	0.000766	0.0625	CbGeAlD
Clomipramine—Chloropyramine—HRH1—atherosclerosis	0.000653	0.0915	CrCbGaD
Clomipramine—Aceprometazine—HRH1—atherosclerosis	0.000645	0.0904	CrCbGaD
Clomipramine—HRH2—cardiovascular system—atherosclerosis	0.0006	0.0489	CbGeAlD
Clomipramine—Clofedanol—HRH1—atherosclerosis	0.000555	0.0778	CrCbGaD
Clomipramine—HTR2A—artery—atherosclerosis	0.000547	0.0446	CbGeAlD
Clomipramine—GSTP1—connective tissue—atherosclerosis	0.000496	0.0405	CbGeAlD
Clomipramine—Olopatadine—HRH1—atherosclerosis	0.000477	0.0669	CrCbGaD
Clomipramine—HTR2A—endothelium—atherosclerosis	0.000462	0.0377	CbGeAlD
Clomipramine—Dimetindene—HRH1—atherosclerosis	0.000444	0.0622	CrCbGaD
Clomipramine—Alimemazine—HRH1—atherosclerosis	0.000435	0.0611	CrCbGaD
Clomipramine—GSTP1—cardiovascular system—atherosclerosis	0.000432	0.0352	CbGeAlD
Clomipramine—HTR2A—blood vessel—atherosclerosis	0.000426	0.0348	CbGeAlD
Clomipramine—GSTP1—adipose tissue—atherosclerosis	0.000381	0.0311	CbGeAlD
Clomipramine—HRH2—liver—atherosclerosis	0.000371	0.0303	CbGeAlD
Clomipramine—HTR2B—cardiovascular system—atherosclerosis	0.000356	0.029	CbGeAlD
Clomipramine—Carbinoxamine—HRH1—atherosclerosis	0.00033	0.0463	CrCbGaD
Clomipramine—HTR2B—adipose tissue—atherosclerosis	0.000314	0.0256	CbGeAlD
Clomipramine—Tinnitus—Niacin—atherosclerosis	0.000298	0.00149	CcSEcCtD
Clomipramine—Dysgeusia—Simvastatin—atherosclerosis	0.000297	0.00148	CcSEcCtD
Clomipramine—Flushing—Niacin—atherosclerosis	0.000297	0.00148	CcSEcCtD
Clomipramine—Ill-defined disorder—Ezetimibe—atherosclerosis	0.000295	0.00147	CcSEcCtD
Clomipramine—Anaemia—Ezetimibe—atherosclerosis	0.000294	0.00147	CcSEcCtD
Clomipramine—Tinnitus—Pravastatin—atherosclerosis	0.000294	0.00147	CcSEcCtD
Clomipramine—Malaise—Lovastatin—atherosclerosis	0.000292	0.00146	CcSEcCtD
Clomipramine—Cardiac disorder—Pravastatin—atherosclerosis	0.000292	0.00146	CcSEcCtD
Clomipramine—Flushing—Pravastatin—atherosclerosis	0.000292	0.00146	CcSEcCtD
Clomipramine—Muscle spasms—Simvastatin—atherosclerosis	0.000292	0.00146	CcSEcCtD
Clomipramine—Vertigo—Lovastatin—atherosclerosis	0.000291	0.00146	CcSEcCtD
Clomipramine—Angiopathy—Niacin—atherosclerosis	0.00029	0.00145	CcSEcCtD
Clomipramine—Leukopenia—Lovastatin—atherosclerosis	0.00029	0.00145	CcSEcCtD
Clomipramine—Chills—Niacin—atherosclerosis	0.000287	0.00143	CcSEcCtD
Clomipramine—Malaise—Ezetimibe—atherosclerosis	0.000287	0.00143	CcSEcCtD
Clomipramine—Vision blurred—Simvastatin—atherosclerosis	0.000286	0.00143	CcSEcCtD
Clomipramine—Arrhythmia—Niacin—atherosclerosis	0.000286	0.00143	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000284	0.00142	CcSEcCtD
Clomipramine—Tremor—Simvastatin—atherosclerosis	0.000284	0.00142	CcSEcCtD
Clomipramine—Alopecia—Niacin—atherosclerosis	0.000283	0.00141	CcSEcCtD
Clomipramine—Chills—Pravastatin—atherosclerosis	0.000283	0.00141	CcSEcCtD
Clomipramine—Insomnia—Rosuvastatin—atherosclerosis	0.000282	0.00141	CcSEcCtD
Clomipramine—Ill-defined disorder—Simvastatin—atherosclerosis	0.000281	0.00141	CcSEcCtD
Clomipramine—Arrhythmia—Pravastatin—atherosclerosis	0.000281	0.00141	CcSEcCtD
Clomipramine—Palpitations—Ezetimibe—atherosclerosis	0.000281	0.0014	CcSEcCtD
Clomipramine—Chlorphenamine—HRH1—atherosclerosis	0.000281	0.0393	CrCbGaD
Clomipramine—Paraesthesia—Rosuvastatin—atherosclerosis	0.00028	0.0014	CcSEcCtD
Clomipramine—Anaemia—Simvastatin—atherosclerosis	0.00028	0.0014	CcSEcCtD
Clomipramine—ABCB1—blood vessel—atherosclerosis	0.000279	0.0228	CbGeAlD
Clomipramine—Malnutrition—Niacin—atherosclerosis	0.000278	0.00139	CcSEcCtD
Clomipramine—Alopecia—Pravastatin—atherosclerosis	0.000278	0.00139	CcSEcCtD
Clomipramine—Cough—Ezetimibe—atherosclerosis	0.000277	0.00139	CcSEcCtD
Clomipramine—Myalgia—Lovastatin—atherosclerosis	0.000276	0.00138	CcSEcCtD
Clomipramine—Chest pain—Lovastatin—atherosclerosis	0.000276	0.00138	CcSEcCtD
Clomipramine—Arthralgia—Lovastatin—atherosclerosis	0.000276	0.00138	CcSEcCtD
Clomipramine—Anxiety—Lovastatin—atherosclerosis	0.000275	0.00137	CcSEcCtD
Clomipramine—Dyspepsia—Rosuvastatin—atherosclerosis	0.000275	0.00137	CcSEcCtD
Clomipramine—Hypertension—Ezetimibe—atherosclerosis	0.000274	0.00137	CcSEcCtD
Clomipramine—Flatulence—Niacin—atherosclerosis	0.000274	0.00137	CcSEcCtD
Clomipramine—Malaise—Simvastatin—atherosclerosis	0.000273	0.00137	CcSEcCtD
Clomipramine—Tension—Niacin—atherosclerosis	0.000273	0.00136	CcSEcCtD
Clomipramine—Discomfort—Lovastatin—atherosclerosis	0.000273	0.00136	CcSEcCtD
Clomipramine—Vertigo—Simvastatin—atherosclerosis	0.000272	0.00136	CcSEcCtD
Clomipramine—Leukopenia—Simvastatin—atherosclerosis	0.000271	0.00136	CcSEcCtD
Clomipramine—Myalgia—Ezetimibe—atherosclerosis	0.000271	0.00135	CcSEcCtD
Clomipramine—Arthralgia—Ezetimibe—atherosclerosis	0.000271	0.00135	CcSEcCtD
Clomipramine—Chest pain—Ezetimibe—atherosclerosis	0.000271	0.00135	CcSEcCtD
Clomipramine—Nervousness—Niacin—atherosclerosis	0.00027	0.00135	CcSEcCtD
Clomipramine—Flatulence—Pravastatin—atherosclerosis	0.00027	0.00135	CcSEcCtD
Clomipramine—Dry mouth—Lovastatin—atherosclerosis	0.00027	0.00135	CcSEcCtD
Clomipramine—Tension—Pravastatin—atherosclerosis	0.000269	0.00134	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.000269	0.00134	CcSEcCtD
Clomipramine—Dysgeusia—Pravastatin—atherosclerosis	0.000268	0.00134	CcSEcCtD
Clomipramine—Muscle spasms—Niacin—atherosclerosis	0.000268	0.00134	CcSEcCtD
Clomipramine—Discomfort—Ezetimibe—atherosclerosis	0.000267	0.00134	CcSEcCtD
Clomipramine—GSTP1—liver—atherosclerosis	0.000267	0.0218	CbGeAlD
Clomipramine—Constipation—Rosuvastatin—atherosclerosis	0.000267	0.00133	CcSEcCtD
Clomipramine—Pain—Rosuvastatin—atherosclerosis	0.000267	0.00133	CcSEcCtD
Clomipramine—Confusional state—Lovastatin—atherosclerosis	0.000267	0.00133	CcSEcCtD
Clomipramine—Nervousness—Pravastatin—atherosclerosis	0.000266	0.00133	CcSEcCtD
Clomipramine—Dry mouth—Ezetimibe—atherosclerosis	0.000265	0.00132	CcSEcCtD
Clomipramine—Anaphylactic shock—Lovastatin—atherosclerosis	0.000265	0.00132	CcSEcCtD
Clomipramine—Muscle spasms—Pravastatin—atherosclerosis	0.000264	0.00132	CcSEcCtD
Clomipramine—Vision blurred—Niacin—atherosclerosis	0.000262	0.00131	CcSEcCtD
Clomipramine—Confusional state—Ezetimibe—atherosclerosis	0.000262	0.00131	CcSEcCtD
Clomipramine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000259	0.0013	CcSEcCtD
Clomipramine—Thrombocytopenia—Lovastatin—atherosclerosis	0.000259	0.00129	CcSEcCtD
Clomipramine—Vision blurred—Pravastatin—atherosclerosis	0.000258	0.00129	CcSEcCtD
Clomipramine—Chest pain—Simvastatin—atherosclerosis	0.000258	0.00129	CcSEcCtD
Clomipramine—Arthralgia—Simvastatin—atherosclerosis	0.000258	0.00129	CcSEcCtD
Clomipramine—Myalgia—Simvastatin—atherosclerosis	0.000258	0.00129	CcSEcCtD
Clomipramine—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000257	0.00129	CcSEcCtD
Clomipramine—Anxiety—Simvastatin—atherosclerosis	0.000257	0.00129	CcSEcCtD
Clomipramine—ADRA2A—connective tissue—atherosclerosis	0.000257	0.021	CbGeAlD
Clomipramine—Tremor—Pravastatin—atherosclerosis	0.000257	0.00128	CcSEcCtD
Clomipramine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000255	0.00128	CcSEcCtD
Clomipramine—Discomfort—Simvastatin—atherosclerosis	0.000255	0.00127	CcSEcCtD
Clomipramine—Prochlorperazine—HRH1—atherosclerosis	0.000255	0.0357	CrCbGaD
Clomipramine—Nervous system disorder—Ezetimibe—atherosclerosis	0.000254	0.00127	CcSEcCtD
Clomipramine—Ill-defined disorder—Pravastatin—atherosclerosis	0.000254	0.00127	CcSEcCtD
Clomipramine—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000254	0.00127	CcSEcCtD
Clomipramine—Anaemia—Pravastatin—atherosclerosis	0.000253	0.00127	CcSEcCtD
Clomipramine—Anorexia—Lovastatin—atherosclerosis	0.000252	0.00126	CcSEcCtD
Clomipramine—Skin disorder—Ezetimibe—atherosclerosis	0.000252	0.00126	CcSEcCtD
Clomipramine—Vertigo—Niacin—atherosclerosis	0.00025	0.00125	CcSEcCtD
Clomipramine—Syncope—Niacin—atherosclerosis	0.00025	0.00125	CcSEcCtD
Clomipramine—Confusional state—Simvastatin—atherosclerosis	0.00025	0.00125	CcSEcCtD
Clomipramine—Leukopenia—Niacin—atherosclerosis	0.000249	0.00125	CcSEcCtD
Clomipramine—Urticaria—Rosuvastatin—atherosclerosis	0.000248	0.00124	CcSEcCtD
Clomipramine—Anaphylactic shock—Simvastatin—atherosclerosis	0.000247	0.00124	CcSEcCtD
Clomipramine—Oedema—Simvastatin—atherosclerosis	0.000247	0.00124	CcSEcCtD
Clomipramine—Malaise—Pravastatin—atherosclerosis	0.000247	0.00124	CcSEcCtD
Clomipramine—Abdominal pain—Rosuvastatin—atherosclerosis	0.000247	0.00123	CcSEcCtD
Clomipramine—Vertigo—Pravastatin—atherosclerosis	0.000246	0.00123	CcSEcCtD
Clomipramine—Palpitations—Niacin—atherosclerosis	0.000246	0.00123	CcSEcCtD
Clomipramine—Leukopenia—Pravastatin—atherosclerosis	0.000245	0.00123	CcSEcCtD
Clomipramine—Loss of consciousness—Niacin—atherosclerosis	0.000245	0.00122	CcSEcCtD
Clomipramine—Cough—Niacin—atherosclerosis	0.000243	0.00121	CcSEcCtD
Clomipramine—Thrombocytopenia—Simvastatin—atherosclerosis	0.000242	0.00121	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000241	0.0012	CcSEcCtD
Clomipramine—Insomnia—Lovastatin—atherosclerosis	0.000239	0.0012	CcSEcCtD
Clomipramine—Cough—Pravastatin—atherosclerosis	0.000239	0.0012	CcSEcCtD
Clomipramine—Paraesthesia—Lovastatin—atherosclerosis	0.000238	0.00119	CcSEcCtD
Clomipramine—Myalgia—Niacin—atherosclerosis	0.000237	0.00118	CcSEcCtD
Clomipramine—Arthralgia—Niacin—atherosclerosis	0.000237	0.00118	CcSEcCtD
Clomipramine—Hypertension—Pravastatin—atherosclerosis	0.000237	0.00118	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000236	0.00118	CcSEcCtD
Clomipramine—Anorexia—Simvastatin—atherosclerosis	0.000236	0.00118	CcSEcCtD
Clomipramine—Dyspnoea—Lovastatin—atherosclerosis	0.000236	0.00118	CcSEcCtD
Clomipramine—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000235	0.00118	CcSEcCtD
Clomipramine—Insomnia—Ezetimibe—atherosclerosis	0.000235	0.00117	CcSEcCtD
Clomipramine—Myalgia—Pravastatin—atherosclerosis	0.000233	0.00117	CcSEcCtD
Clomipramine—Chest pain—Pravastatin—atherosclerosis	0.000233	0.00117	CcSEcCtD
Clomipramine—Arthralgia—Pravastatin—atherosclerosis	0.000233	0.00117	CcSEcCtD
Clomipramine—Paraesthesia—Ezetimibe—atherosclerosis	0.000233	0.00116	CcSEcCtD
Clomipramine—Dyspepsia—Lovastatin—atherosclerosis	0.000233	0.00116	CcSEcCtD
Clomipramine—Anxiety—Pravastatin—atherosclerosis	0.000233	0.00116	CcSEcCtD
Clomipramine—Dry mouth—Niacin—atherosclerosis	0.000232	0.00116	CcSEcCtD
Clomipramine—Dyspnoea—Ezetimibe—atherosclerosis	0.000231	0.00116	CcSEcCtD
Clomipramine—Discomfort—Pravastatin—atherosclerosis	0.000231	0.00115	CcSEcCtD
Clomipramine—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00023	0.00115	CcSEcCtD
Clomipramine—Decreased appetite—Lovastatin—atherosclerosis	0.00023	0.00115	CcSEcCtD
Clomipramine—ALB—liver—atherosclerosis	0.000229	0.0187	CbGeAlD
Clomipramine—Dyspepsia—Ezetimibe—atherosclerosis	0.000228	0.00114	CcSEcCtD
Clomipramine—Fatigue—Lovastatin—atherosclerosis	0.000228	0.00114	CcSEcCtD
Clomipramine—Oedema—Niacin—atherosclerosis	0.000227	0.00114	CcSEcCtD
Clomipramine—Anaphylactic shock—Niacin—atherosclerosis	0.000227	0.00114	CcSEcCtD
Clomipramine—Pain—Lovastatin—atherosclerosis	0.000226	0.00113	CcSEcCtD
Clomipramine—Constipation—Lovastatin—atherosclerosis	0.000226	0.00113	CcSEcCtD
Clomipramine—Confusional state—Pravastatin—atherosclerosis	0.000226	0.00113	CcSEcCtD
Clomipramine—Decreased appetite—Ezetimibe—atherosclerosis	0.000226	0.00113	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000225	0.00113	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000224	0.00112	CcSEcCtD
Clomipramine—Asthenia—Rosuvastatin—atherosclerosis	0.000224	0.00112	CcSEcCtD
Clomipramine—Insomnia—Simvastatin—atherosclerosis	0.000224	0.00112	CcSEcCtD
Clomipramine—Anaphylactic shock—Pravastatin—atherosclerosis	0.000224	0.00112	CcSEcCtD
Clomipramine—Oedema—Pravastatin—atherosclerosis	0.000224	0.00112	CcSEcCtD
Clomipramine—Fatigue—Ezetimibe—atherosclerosis	0.000224	0.00112	CcSEcCtD
Clomipramine—Shock—Niacin—atherosclerosis	0.000224	0.00112	CcSEcCtD
Clomipramine—Paraesthesia—Simvastatin—atherosclerosis	0.000222	0.00111	CcSEcCtD
Clomipramine—Constipation—Ezetimibe—atherosclerosis	0.000222	0.00111	CcSEcCtD
Clomipramine—Pain—Ezetimibe—atherosclerosis	0.000222	0.00111	CcSEcCtD
Clomipramine—Tachycardia—Niacin—atherosclerosis	0.000222	0.00111	CcSEcCtD
Clomipramine—Propiomazine—HRH1—atherosclerosis	0.000222	0.0311	CrCbGaD
Clomipramine—Pruritus—Rosuvastatin—atherosclerosis	0.000221	0.0011	CcSEcCtD
Clomipramine—Skin disorder—Niacin—atherosclerosis	0.000221	0.0011	CcSEcCtD
Clomipramine—Dyspnoea—Simvastatin—atherosclerosis	0.000221	0.0011	CcSEcCtD
Clomipramine—Hyperhidrosis—Niacin—atherosclerosis	0.00022	0.0011	CcSEcCtD
Clomipramine—Thrombocytopenia—Pravastatin—atherosclerosis	0.000219	0.00109	CcSEcCtD
Clomipramine—HTR2A—connective tissue—atherosclerosis	0.000219	0.0178	CbGeAlD
Clomipramine—Feeling abnormal—Lovastatin—atherosclerosis	0.000218	0.00109	CcSEcCtD
Clomipramine—Dyspepsia—Simvastatin—atherosclerosis	0.000218	0.00109	CcSEcCtD
Clomipramine—Anorexia—Niacin—atherosclerosis	0.000217	0.00108	CcSEcCtD
Clomipramine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000216	0.00108	CcSEcCtD
Clomipramine—Hyperhidrosis—Pravastatin—atherosclerosis	0.000216	0.00108	CcSEcCtD
Clomipramine—Decreased appetite—Simvastatin—atherosclerosis	0.000215	0.00107	CcSEcCtD
Clomipramine—Feeling abnormal—Ezetimibe—atherosclerosis	0.000214	0.00107	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000214	0.00107	CcSEcCtD
Clomipramine—Diarrhoea—Rosuvastatin—atherosclerosis	0.000214	0.00107	CcSEcCtD
Clomipramine—Fatigue—Simvastatin—atherosclerosis	0.000213	0.00107	CcSEcCtD
Clomipramine—Anorexia—Pravastatin—atherosclerosis	0.000213	0.00107	CcSEcCtD
Clomipramine—Hypotension—Niacin—atherosclerosis	0.000212	0.00106	CcSEcCtD
Clomipramine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000212	0.00106	CcSEcCtD
Clomipramine—Constipation—Simvastatin—atherosclerosis	0.000212	0.00106	CcSEcCtD
Clomipramine—Pain—Simvastatin—atherosclerosis	0.000212	0.00106	CcSEcCtD
Clomipramine—Urticaria—Lovastatin—atherosclerosis	0.00021	0.00105	CcSEcCtD
Clomipramine—Chlorprothixene—HRH1—atherosclerosis	0.00021	0.0294	CrCbGaD
Clomipramine—Body temperature increased—Lovastatin—atherosclerosis	0.000209	0.00104	CcSEcCtD
Clomipramine—Abdominal pain—Lovastatin—atherosclerosis	0.000209	0.00104	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000207	0.00103	CcSEcCtD
Clomipramine—Dizziness—Rosuvastatin—atherosclerosis	0.000206	0.00103	CcSEcCtD
Clomipramine—Urticaria—Ezetimibe—atherosclerosis	0.000206	0.00103	CcSEcCtD
Clomipramine—Nortriptyline—HRH1—atherosclerosis	0.000206	0.0289	CrCbGaD
Clomipramine—Insomnia—Niacin—atherosclerosis	0.000206	0.00103	CcSEcCtD
Clomipramine—Body temperature increased—Ezetimibe—atherosclerosis	0.000205	0.00102	CcSEcCtD
Clomipramine—Abdominal pain—Ezetimibe—atherosclerosis	0.000205	0.00102	CcSEcCtD
Clomipramine—Paraesthesia—Niacin—atherosclerosis	0.000204	0.00102	CcSEcCtD
Clomipramine—Feeling abnormal—Simvastatin—atherosclerosis	0.000204	0.00102	CcSEcCtD
Clomipramine—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000204	0.00102	CcSEcCtD
Clomipramine—Dyspnoea—Niacin—atherosclerosis	0.000203	0.00101	CcSEcCtD
Clomipramine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000202	0.00101	CcSEcCtD
Clomipramine—Insomnia—Pravastatin—atherosclerosis	0.000202	0.00101	CcSEcCtD
Clomipramine—Somnolence—Niacin—atherosclerosis	0.000202	0.00101	CcSEcCtD
Clomipramine—Paraesthesia—Pravastatin—atherosclerosis	0.000201	0.001	CcSEcCtD
Clomipramine—Dyspepsia—Niacin—atherosclerosis	0.0002	0.000999	CcSEcCtD
Clomipramine—Dyspnoea—Pravastatin—atherosclerosis	0.000199	0.000997	CcSEcCtD
Clomipramine—Thioridazine—HRH1—atherosclerosis	0.000199	0.0278	CrCbGaD
Clomipramine—Decreased appetite—Niacin—atherosclerosis	0.000198	0.000987	CcSEcCtD
Clomipramine—ADRA2A—adipose tissue—atherosclerosis	0.000197	0.0161	CbGeAlD
Clomipramine—Dyspepsia—Pravastatin—atherosclerosis	0.000197	0.000984	CcSEcCtD
Clomipramine—Rash—Rosuvastatin—atherosclerosis	0.000197	0.000983	CcSEcCtD
Clomipramine—Dermatitis—Rosuvastatin—atherosclerosis	0.000197	0.000983	CcSEcCtD
Clomipramine—Urticaria—Simvastatin—atherosclerosis	0.000197	0.000982	CcSEcCtD
Clomipramine—Gastrointestinal disorder—Niacin—atherosclerosis	0.000196	0.00098	CcSEcCtD
Clomipramine—Abdominal pain—Simvastatin—atherosclerosis	0.000196	0.000977	CcSEcCtD
Clomipramine—Body temperature increased—Simvastatin—atherosclerosis	0.000196	0.000977	CcSEcCtD
Clomipramine—Headache—Rosuvastatin—atherosclerosis	0.000196	0.000977	CcSEcCtD
Clomipramine—Hypersensitivity—Lovastatin—atherosclerosis	0.000195	0.000974	CcSEcCtD
Clomipramine—Decreased appetite—Pravastatin—atherosclerosis	0.000194	0.000972	CcSEcCtD
Clomipramine—Pain—Niacin—atherosclerosis	0.000194	0.000971	CcSEcCtD
Clomipramine—Trimipramine—HRH1—atherosclerosis	0.000194	0.0272	CrCbGaD
Clomipramine—Fatigue—Pravastatin—atherosclerosis	0.000193	0.000964	CcSEcCtD
Clomipramine—Pain—Pravastatin—atherosclerosis	0.000191	0.000956	CcSEcCtD
Clomipramine—Constipation—Pravastatin—atherosclerosis	0.000191	0.000956	CcSEcCtD
Clomipramine—Hypersensitivity—Ezetimibe—atherosclerosis	0.000191	0.000955	CcSEcCtD
Clomipramine—HTR2A—cardiovascular system—atherosclerosis	0.00019	0.0155	CbGeAlD
Clomipramine—Asthenia—Lovastatin—atherosclerosis	0.00019	0.000948	CcSEcCtD
Clomipramine—Methotrimeprazine—HRH1—atherosclerosis	0.00019	0.0266	CrCbGaD
Clomipramine—Pruritus—Lovastatin—atherosclerosis	0.000187	0.000935	CcSEcCtD
Clomipramine—Promethazine—HRH1—atherosclerosis	0.000187	0.0262	CrCbGaD
Clomipramine—Asthenia—Ezetimibe—atherosclerosis	0.000186	0.00093	CcSEcCtD
Clomipramine—Gastrointestinal pain—Niacin—atherosclerosis	0.000186	0.000928	CcSEcCtD
Clomipramine—Nausea—Rosuvastatin—atherosclerosis	0.000185	0.000926	CcSEcCtD
Clomipramine—Doxepin—HRH1—atherosclerosis	0.000185	0.0259	CrCbGaD
Clomipramine—Feeling abnormal—Pravastatin—atherosclerosis	0.000184	0.000921	CcSEcCtD
Clomipramine—Trifluoperazine—HRH1—atherosclerosis	0.000184	0.0258	CrCbGaD
Clomipramine—CYP2C19—liver—atherosclerosis	0.000184	0.015	CbGeAlD
Clomipramine—Pruritus—Ezetimibe—atherosclerosis	0.000184	0.000917	CcSEcCtD
Clomipramine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000183	0.000914	CcSEcCtD
Clomipramine—Hypersensitivity—Simvastatin—atherosclerosis	0.000182	0.000911	CcSEcCtD
Clomipramine—Perphenazine—HRH1—atherosclerosis	0.000182	0.0255	CrCbGaD
Clomipramine—Diarrhoea—Lovastatin—atherosclerosis	0.000181	0.000904	CcSEcCtD
Clomipramine—Urticaria—Niacin—atherosclerosis	0.000181	0.000902	CcSEcCtD
Clomipramine—Abdominal pain—Niacin—atherosclerosis	0.00018	0.000897	CcSEcCtD
Clomipramine—Body temperature increased—Niacin—atherosclerosis	0.00018	0.000897	CcSEcCtD
Clomipramine—Urticaria—Pravastatin—atherosclerosis	0.000178	0.000888	CcSEcCtD
Clomipramine—Asthenia—Simvastatin—atherosclerosis	0.000178	0.000887	CcSEcCtD
Clomipramine—Diarrhoea—Ezetimibe—atherosclerosis	0.000178	0.000887	CcSEcCtD
Clomipramine—Abdominal pain—Pravastatin—atherosclerosis	0.000177	0.000884	CcSEcCtD
Clomipramine—Body temperature increased—Pravastatin—atherosclerosis	0.000177	0.000884	CcSEcCtD
Clomipramine—Pruritus—Simvastatin—atherosclerosis	0.000175	0.000875	CcSEcCtD
Clomipramine—Dizziness—Lovastatin—atherosclerosis	0.000175	0.000874	CcSEcCtD
Clomipramine—Dizziness—Ezetimibe—atherosclerosis	0.000172	0.000857	CcSEcCtD
Clomipramine—Desipramine—HRH1—atherosclerosis	0.00017	0.0238	CrCbGaD
Clomipramine—Diarrhoea—Simvastatin—atherosclerosis	0.000169	0.000846	CcSEcCtD
Clomipramine—Vomiting—Lovastatin—atherosclerosis	0.000168	0.00084	CcSEcCtD
Clomipramine—Hypersensitivity—Niacin—atherosclerosis	0.000167	0.000836	CcSEcCtD
Clomipramine—Rash—Lovastatin—atherosclerosis	0.000167	0.000833	CcSEcCtD
Clomipramine—Dermatitis—Lovastatin—atherosclerosis	0.000167	0.000833	CcSEcCtD
Clomipramine—Headache—Lovastatin—atherosclerosis	0.000166	0.000828	CcSEcCtD
Clomipramine—Vomiting—Ezetimibe—atherosclerosis	0.000165	0.000824	CcSEcCtD
Clomipramine—Hypersensitivity—Pravastatin—atherosclerosis	0.000165	0.000824	CcSEcCtD
Clomipramine—Promazine—HRH1—atherosclerosis	0.000164	0.023	CrCbGaD
Clomipramine—Dizziness—Simvastatin—atherosclerosis	0.000164	0.000818	CcSEcCtD
Clomipramine—Rash—Ezetimibe—atherosclerosis	0.000164	0.000817	CcSEcCtD
Clomipramine—Dermatitis—Ezetimibe—atherosclerosis	0.000163	0.000817	CcSEcCtD
Clomipramine—Asthenia—Niacin—atherosclerosis	0.000163	0.000815	CcSEcCtD
Clomipramine—Headache—Ezetimibe—atherosclerosis	0.000163	0.000812	CcSEcCtD
Clomipramine—Pruritus—Niacin—atherosclerosis	0.000161	0.000803	CcSEcCtD
Clomipramine—Asthenia—Pravastatin—atherosclerosis	0.000161	0.000802	CcSEcCtD
Clomipramine—Pruritus—Pravastatin—atherosclerosis	0.000158	0.000791	CcSEcCtD
Clomipramine—Vomiting—Simvastatin—atherosclerosis	0.000157	0.000786	CcSEcCtD
Clomipramine—Nausea—Lovastatin—atherosclerosis	0.000157	0.000785	CcSEcCtD
Clomipramine—Rash—Simvastatin—atherosclerosis	0.000156	0.00078	CcSEcCtD
Clomipramine—Dermatitis—Simvastatin—atherosclerosis	0.000156	0.000779	CcSEcCtD
Clomipramine—Diarrhoea—Niacin—atherosclerosis	0.000155	0.000777	CcSEcCtD
Clomipramine—Headache—Simvastatin—atherosclerosis	0.000155	0.000775	CcSEcCtD
Clomipramine—Nausea—Ezetimibe—atherosclerosis	0.000154	0.00077	CcSEcCtD
Clomipramine—Diarrhoea—Pravastatin—atherosclerosis	0.000153	0.000765	CcSEcCtD
Clomipramine—CYP1A2—liver—atherosclerosis	0.00015	0.0123	CbGeAlD
Clomipramine—Dizziness—Niacin—atherosclerosis	0.00015	0.000751	CcSEcCtD
Clomipramine—Dizziness—Pravastatin—atherosclerosis	0.000148	0.000739	CcSEcCtD
Clomipramine—Nausea—Simvastatin—atherosclerosis	0.000147	0.000734	CcSEcCtD
Clomipramine—Chlorpromazine—HRH1—atherosclerosis	0.000145	0.0203	CrCbGaD
Clomipramine—Vomiting—Niacin—atherosclerosis	0.000144	0.000722	CcSEcCtD
Clomipramine—Imipramine—HRH1—atherosclerosis	0.000144	0.0202	CrCbGaD
Clomipramine—Rash—Niacin—atherosclerosis	0.000143	0.000716	CcSEcCtD
Clomipramine—Dermatitis—Niacin—atherosclerosis	0.000143	0.000715	CcSEcCtD
Clomipramine—Amitriptyline—HRH1—atherosclerosis	0.000143	0.02	CrCbGaD
Clomipramine—Headache—Niacin—atherosclerosis	0.000142	0.000711	CcSEcCtD
Clomipramine—Vomiting—Pravastatin—atherosclerosis	0.000142	0.000711	CcSEcCtD
Clomipramine—Rash—Pravastatin—atherosclerosis	0.000141	0.000705	CcSEcCtD
Clomipramine—Dermatitis—Pravastatin—atherosclerosis	0.000141	0.000704	CcSEcCtD
Clomipramine—Headache—Pravastatin—atherosclerosis	0.00014	0.0007	CcSEcCtD
Clomipramine—Nausea—Niacin—atherosclerosis	0.000135	0.000674	CcSEcCtD
Clomipramine—Nausea—Pravastatin—atherosclerosis	0.000133	0.000664	CcSEcCtD
Clomipramine—ABCB1—cardiovascular system—atherosclerosis	0.000125	0.0102	CbGeAlD
Clomipramine—HTR2A—liver—atherosclerosis	0.000118	0.00959	CbGeAlD
Clomipramine—ABCB1—adipose tissue—atherosclerosis	0.00011	0.00896	CbGeAlD
Clomipramine—CYP3A4—liver—atherosclerosis	0.000109	0.00888	CbGeAlD
Clomipramine—CYP2D6—liver—atherosclerosis	0.000107	0.00874	CbGeAlD
Clomipramine—ABCB1—liver—atherosclerosis	7.71e-05	0.00629	CbGeAlD
Clomipramine—Acepromazine—ALB—atherosclerosis	6.4e-05	0.00898	CrCbGaD
Clomipramine—Thioproperazine—ALB—atherosclerosis	6.26e-05	0.00877	CrCbGaD
Clomipramine—Pipotiazine—ALB—atherosclerosis	6.16e-05	0.00863	CrCbGaD
Clomipramine—Nortriptyline—ALB—atherosclerosis	4.76e-05	0.00667	CrCbGaD
Clomipramine—Diazepam—ALB—atherosclerosis	3.59e-05	0.00504	CrCbGaD
Clomipramine—Chlorpromazine—ALB—atherosclerosis	3.34e-05	0.00468	CrCbGaD
Clomipramine—Amitriptyline—ALB—atherosclerosis	3.3e-05	0.00463	CrCbGaD
Clomipramine—ALB—Hemostasis—MAPK3—atherosclerosis	7.03e-06	5.72e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—CAV1—atherosclerosis	7.01e-06	5.7e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ABCA1—atherosclerosis	7.01e-06	5.7e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—APOA1—atherosclerosis	6.99e-06	5.69e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—APOB—atherosclerosis	6.97e-06	5.68e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NOS3—atherosclerosis	6.95e-06	5.66e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	6.87e-06	5.59e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PRKCG—atherosclerosis	6.86e-06	5.58e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	6.84e-06	5.57e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—TGFB1—atherosclerosis	6.82e-06	5.55e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	6.8e-06	5.53e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GSTM1—atherosclerosis	6.78e-06	5.52e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—MAPK3—atherosclerosis	6.77e-06	5.51e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	6.76e-06	5.5e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—CXCL8—atherosclerosis	6.75e-06	5.5e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SPP1—atherosclerosis	6.68e-06	5.44e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—HMGCR—atherosclerosis	6.66e-06	5.42e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—LPL—atherosclerosis	6.66e-06	5.42e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—CXCL8—atherosclerosis	6.65e-06	5.41e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AGT—atherosclerosis	6.63e-06	5.4e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ALOX5—atherosclerosis	6.61e-06	5.38e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—TGFB1—atherosclerosis	6.57e-06	5.34e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—HMOX1—atherosclerosis	6.54e-06	5.32e-05	CbGpPWpGaD
Clomipramine—HTR6—GPCR downstream signaling—AKT1—atherosclerosis	6.53e-06	5.31e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—LEP—atherosclerosis	6.5e-06	5.29e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—APOE—atherosclerosis	6.5e-06	5.29e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—GPX1—atherosclerosis	6.5e-06	5.29e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	6.47e-06	5.27e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CAV1—atherosclerosis	6.44e-06	5.24e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—APOA1—atherosclerosis	6.43e-06	5.23e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—IL6—atherosclerosis	6.42e-06	5.23e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—INS—atherosclerosis	6.39e-06	5.2e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PIK3CG—atherosclerosis	6.38e-06	5.2e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—HMOX1—atherosclerosis	6.38e-06	5.19e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CD36—atherosclerosis	6.33e-06	5.15e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CCL2—atherosclerosis	6.29e-06	5.12e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—APOB—atherosclerosis	6.26e-06	5.1e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—ESR1—atherosclerosis	6.21e-06	5.05e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IGF1—atherosclerosis	6.19e-06	5.03e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PDGFB—atherosclerosis	6.18e-06	5.03e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	6.17e-06	5.02e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PPARG—atherosclerosis	6.16e-06	5.01e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—F2—atherosclerosis	6.13e-06	4.99e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—APOB—atherosclerosis	6.11e-06	4.97e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MMP9—atherosclerosis	6.11e-06	4.97e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GSTM1—atherosclerosis	6.09e-06	4.96e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—NFKB1—atherosclerosis	6.04e-06	4.92e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—INS—atherosclerosis	6.04e-06	4.92e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AGT—atherosclerosis	6.04e-06	4.91e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—HMOX1—atherosclerosis	6.01e-06	4.89e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Hemostasis—AKT1—atherosclerosis	6.01e-06	4.89e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	6.01e-06	4.89e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—MTHFR—atherosclerosis	6e-06	4.88e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—LPL—atherosclerosis	5.98e-06	4.87e-05	CbGpPWpGaD
Clomipramine—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	5.96e-06	4.85e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GSTM1—atherosclerosis	5.94e-06	4.84e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MAPK8—atherosclerosis	5.94e-06	4.84e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ABCA1—atherosclerosis	5.94e-06	4.83e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NAMPT—atherosclerosis	5.93e-06	4.82e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling by GPCR—AKT1—atherosclerosis	5.93e-06	4.82e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—LEP—atherosclerosis	5.91e-06	4.81e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—APOE—atherosclerosis	5.91e-06	4.81e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—LIPC—atherosclerosis	5.89e-06	4.79e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PPARA—atherosclerosis	5.88e-06	4.79e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	5.87e-06	4.78e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	5.87e-06	4.77e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—IL6—atherosclerosis	5.86e-06	4.77e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CAV1—atherosclerosis	5.86e-06	4.77e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—APOC3—atherosclerosis	5.85e-06	4.76e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—APOA1—atherosclerosis	5.85e-06	4.76e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—LPL—atherosclerosis	5.83e-06	4.75e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—GPX1—atherosclerosis	5.83e-06	4.75e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—LDLR—atherosclerosis	5.82e-06	4.74e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—APOB—atherosclerosis	5.76e-06	4.69e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AGT—atherosclerosis	5.7e-06	4.64e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—GPX1—atherosclerosis	5.69e-06	4.63e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CETP—atherosclerosis	5.68e-06	4.63e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CD36—atherosclerosis	5.68e-06	4.62e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—ESR1—atherosclerosis	5.65e-06	4.6e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	5.62e-06	4.57e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	5.61e-06	4.56e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GSTM1—atherosclerosis	5.6e-06	4.56e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—APOE—atherosclerosis	5.58e-06	4.54e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MMP9—atherosclerosis	5.58e-06	4.54e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—F2—atherosclerosis	5.58e-06	4.54e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—INS—atherosclerosis	5.55e-06	4.52e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CD36—atherosclerosis	5.54e-06	4.51e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—ALB—atherosclerosis	5.54e-06	4.51e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—CAV1—atherosclerosis	5.53e-06	4.5e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	5.52e-06	4.49e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—APOA1—atherosclerosis	5.52e-06	4.49e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—LPL—atherosclerosis	5.5e-06	4.47e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—VEGFA—atherosclerosis	5.49e-06	4.47e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	5.46e-06	4.45e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—SCARB1—atherosclerosis	5.44e-06	4.43e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—STAT3—atherosclerosis	5.43e-06	4.42e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	5.42e-06	4.41e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	5.41e-06	4.4e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—MTHFR—atherosclerosis	5.38e-06	4.38e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	5.37e-06	4.37e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—GPX1—atherosclerosis	5.36e-06	4.37e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—PIK3CG—atherosclerosis	5.34e-06	4.34e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—NOS3—atherosclerosis	5.3e-06	4.31e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PPARA—atherosclerosis	5.28e-06	4.3e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—MTHFR—atherosclerosis	5.25e-06	4.28e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CD36—atherosclerosis	5.22e-06	4.25e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—MAPK3—atherosclerosis	5.19e-06	4.22e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PPARA—atherosclerosis	5.15e-06	4.19e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—HMGCR—atherosclerosis	5.14e-06	4.18e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AGT—atherosclerosis	5.11e-06	4.16e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—MAPK3—atherosclerosis	5.11e-06	4.16e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	5.1e-06	4.15e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—HMOX1—atherosclerosis	5.09e-06	4.14e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—INS—atherosclerosis	5.05e-06	4.11e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PIK3CG—atherosclerosis	5.04e-06	4.1e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—TGFB1—atherosclerosis	5.04e-06	4.1e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—APOE—atherosclerosis	5.01e-06	4.08e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	5.01e-06	4.08e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AGT—atherosclerosis	4.99e-06	4.06e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	4.97e-06	4.05e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CCL2—atherosclerosis	4.97e-06	4.05e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—CAV1—atherosclerosis	4.96e-06	4.04e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—STAT3—atherosclerosis	4.96e-06	4.04e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—APOA1—atherosclerosis	4.95e-06	4.03e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—MTHFR—atherosclerosis	4.95e-06	4.03e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—IL6—atherosclerosis	4.95e-06	4.03e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—APOE—atherosclerosis	4.89e-06	3.98e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IGF1—atherosclerosis	4.89e-06	3.98e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—APOB—atherosclerosis	4.88e-06	3.97e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	4.87e-06	3.96e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PPARG—atherosclerosis	4.86e-06	3.96e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PPARA—atherosclerosis	4.86e-06	3.95e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—PTGS2—atherosclerosis	4.85e-06	3.94e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—CAV1—atherosclerosis	4.85e-06	3.94e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—APOA1—atherosclerosis	4.83e-06	3.93e-05	CbGpPWpGaD
Clomipramine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	4.81e-06	3.91e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—INS—atherosclerosis	4.77e-06	3.88e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GSTM1—atherosclerosis	4.74e-06	3.86e-05	CbGpPWpGaD
Clomipramine—ALB—Hemostasis—AKT1—atherosclerosis	4.74e-06	3.86e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	4.74e-06	3.86e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	4.73e-06	3.85e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AGT—atherosclerosis	4.7e-06	3.83e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—LPL—atherosclerosis	4.66e-06	3.79e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—SERPINE1—atherosclerosis	4.64e-06	3.78e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—APOE—atherosclerosis	4.61e-06	3.75e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	4.6e-06	3.74e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ABCA1—atherosclerosis	4.58e-06	3.73e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—CAV1—atherosclerosis	4.57e-06	3.72e-05	CbGpPWpGaD
Clomipramine—HRH2—Signaling Pathways—AKT1—atherosclerosis	4.56e-06	3.71e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—APOA1—atherosclerosis	4.56e-06	3.71e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—GPX1—atherosclerosis	4.54e-06	3.7e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PIK3CG—atherosclerosis	4.52e-06	3.68e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	4.5e-06	3.66e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	4.45e-06	3.62e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NOS3—atherosclerosis	4.43e-06	3.61e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CD36—atherosclerosis	4.43e-06	3.6e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PIK3CG—atherosclerosis	4.41e-06	3.59e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	4.38e-06	3.56e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PPARG—atherosclerosis	4.36e-06	3.55e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	4.36e-06	3.55e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	4.32e-06	3.52e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—INS—atherosclerosis	4.28e-06	3.48e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PPARG—atherosclerosis	4.26e-06	3.47e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—MTHFR—atherosclerosis	4.19e-06	3.41e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—NOS3—atherosclerosis	4.18e-06	3.4e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—INS—atherosclerosis	4.18e-06	3.4e-05	CbGpPWpGaD
Clomipramine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	4.17e-06	3.4e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PIK3CG—atherosclerosis	4.16e-06	3.39e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PPARA—atherosclerosis	4.11e-06	3.35e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	4.11e-06	3.34e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	4.04e-06	3.29e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PPARG—atherosclerosis	4.01e-06	3.27e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	4e-06	3.26e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AGT—atherosclerosis	3.98e-06	3.24e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—INS—atherosclerosis	3.94e-06	3.2e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.93e-06	3.2e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—CXCL8—atherosclerosis	3.93e-06	3.2e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—ALB—atherosclerosis	3.92e-06	3.19e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	3.91e-06	3.18e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—APOE—atherosclerosis	3.9e-06	3.18e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—CAV1—atherosclerosis	3.87e-06	3.15e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	3.87e-06	3.15e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—APOA1—atherosclerosis	3.86e-06	3.14e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—ALB—atherosclerosis	3.83e-06	3.12e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—PTGS2—atherosclerosis	3.82e-06	3.11e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	3.82e-06	3.11e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	3.8e-06	3.09e-05	CbGpPWpGaD
Clomipramine—ADRA2A—GPCR downstream signaling—AKT1—atherosclerosis	3.8e-06	3.09e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—IL6—atherosclerosis	3.79e-06	3.09e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	3.79e-06	3.08e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—APOB—atherosclerosis	3.76e-06	3.06e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—NOS3—atherosclerosis	3.75e-06	3.06e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—IL6—atherosclerosis	3.74e-06	3.04e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	3.71e-06	3.02e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—NOS3—atherosclerosis	3.66e-06	2.98e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GSTM1—atherosclerosis	3.66e-06	2.98e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—ALB—atherosclerosis	3.61e-06	2.94e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—LPL—atherosclerosis	3.59e-06	2.93e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MMP9—atherosclerosis	3.55e-06	2.89e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PIK3CG—atherosclerosis	3.52e-06	2.87e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—NFKB1—atherosclerosis	3.52e-06	2.86e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	3.51e-06	2.86e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—GPX1—atherosclerosis	3.51e-06	2.85e-05	CbGpPWpGaD
Clomipramine—HTR6—Signaling Pathways—AKT1—atherosclerosis	3.5e-06	2.85e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	3.47e-06	2.83e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—IL6—atherosclerosis	3.46e-06	2.82e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MAPK8—atherosclerosis	3.46e-06	2.81e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—NOS3—atherosclerosis	3.45e-06	2.81e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling by GPCR—AKT1—atherosclerosis	3.45e-06	2.81e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—PTGS2—atherosclerosis	3.43e-06	2.79e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CD36—atherosclerosis	3.42e-06	2.78e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PPARG—atherosclerosis	3.4e-06	2.77e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—PTGS2—atherosclerosis	3.35e-06	2.73e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—INS—atherosclerosis	3.34e-06	2.71e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	3.32e-06	2.7e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—MTHFR—atherosclerosis	3.24e-06	2.63e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	3.22e-06	2.62e-05	CbGpPWpGaD
Clomipramine—HTR2B—Signaling Pathways—AKT1—atherosclerosis	3.2e-06	2.6e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—VEGFA—atherosclerosis	3.19e-06	2.6e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PPARA—atherosclerosis	3.18e-06	2.58e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—STAT3—atherosclerosis	3.16e-06	2.57e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—PTGS2—atherosclerosis	3.16e-06	2.57e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AGT—atherosclerosis	3.08e-06	2.5e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—ALB—atherosclerosis	3.06e-06	2.49e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—MAPK3—atherosclerosis	3.02e-06	2.46e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—APOE—atherosclerosis	3.01e-06	2.45e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—CAV1—atherosclerosis	2.99e-06	2.43e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—APOA1—atherosclerosis	2.98e-06	2.42e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—TGFB1—atherosclerosis	2.93e-06	2.38e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—NOS3—atherosclerosis	2.92e-06	2.38e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.79e-06	2.27e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.72e-06	2.21e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.67e-06	2.18e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PPARG—atherosclerosis	2.62e-06	2.14e-05	CbGpPWpGaD
Clomipramine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	2.58e-06	2.1e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—INS—atherosclerosis	2.57e-06	2.1e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Metabolism—AKT1—atherosclerosis	2.44e-06	1.98e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—IL6—atherosclerosis	2.43e-06	1.97e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—ALB—atherosclerosis	2.36e-06	1.92e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—NOS3—atherosclerosis	2.26e-06	1.84e-05	CbGpPWpGaD
Clomipramine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	2.24e-06	1.82e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—IL6—atherosclerosis	2.21e-06	1.8e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—PTGS2—atherosclerosis	2.06e-06	1.68e-05	CbGpPWpGaD
Clomipramine—ADRA2A—Signaling Pathways—AKT1—atherosclerosis	2.04e-06	1.66e-05	CbGpPWpGaD
Clomipramine—ALB—Metabolism—AKT1—atherosclerosis	1.92e-06	1.56e-05	CbGpPWpGaD
Clomipramine—CYP2C19—Metabolism—AKT1—atherosclerosis	1.73e-06	1.4e-05	CbGpPWpGaD
Clomipramine—ABCB1—Metabolism—AKT1—atherosclerosis	1.68e-06	1.37e-05	CbGpPWpGaD
Clomipramine—CYP2D6—Metabolism—AKT1—atherosclerosis	1.59e-06	1.29e-05	CbGpPWpGaD
Clomipramine—CYP1A2—Metabolism—AKT1—atherosclerosis	1.34e-06	1.09e-05	CbGpPWpGaD
Clomipramine—CYP3A4—Metabolism—AKT1—atherosclerosis	1.04e-06	8.45e-06	CbGpPWpGaD
